Q-omics provides the consensus-scored GRIA1 profile across patient tissues and cancer cell-line models. GRIA1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, GRIA1 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, GRIA1 RNA expression shows 10,925 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, LUAD, and TGCT as cancer lineages where GRIA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRIA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRIA1 survival associations across molecular data types. GRIA1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRIA1 RNA expression–survival associations across cancer types. High GRIA1 expression shows unfavorable associations in OV, KIRP and LUSC, but favorable associations in ACC, LUAD and LGG. The OV Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for GRIA1 RNA expression.
This table summarizes GRIA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for GRIA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRIA1 shows lower tumor expression in LUAD, BLCA, THCA, COAD, LUSC and HNSC. The LUAD box plot shows higher GRIA1 RNA expression in normal versus tumor tissue (log2 FC = −3.098, t-test p < 0.001).
This table shows molecular features associated with GRIA1 in patient tissues and cancer cell lines. In patient samples, GRIA1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRIA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
